Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-80 years old~* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder~* The patient's current depressive episode must be at least 4 weeks in duration~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for: a. any manic or hypomanic episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive disorder.~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo capsules, oral administration, once daily dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).